Chemed Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Chemed stock.
View analyst ratings for Chemed or view top-rated stocks.

Wall Street analysts have given Chemed a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Chemed wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Chemed saw a increase in short interest in August. As of August 13th, there was short interest totaling 198,000 shares, an increase of 12.5% from the July 29th total of 176,000 shares. Based on an average trading volume of 90,500 shares, the days-to-cover ratio is presently 2.2 days. Approximately 1.3% of the shares of the stock are sold short.
View Chemed's Short Interest.

Chemed is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Chemed.

Chemed Co. (NYSE:CHE) released its quarterly earnings data on Monday, July, 26th. The company reported $4.60 earnings per share for the quarter, topping the Zacks' consensus estimate of $4.29 by $0.31. The firm had revenue of $532.26 million for the quarter, compared to analyst estimates of $511.85 million. Chemed had a net margin of 14.30% and a trailing twelve-month return on equity of 35.40%. Chemed's quarterly revenue was up 6.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $4.41 earnings per share.
View Chemed's earnings history.

Chemed's stock was trading at $414.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CHE shares have increased by 14.3% and is now trading at $473.08.
View which stocks have been most impacted by COVID-19.

Chemed declared a quarterly dividend on Friday, August 6th. Stockholders of record on Monday, August 16th will be given a dividend of $0.36 per share on Thursday, September 2nd. This represents a $1.44 annualized dividend and a dividend yield of 0.30%. The ex-dividend date of this dividend is Friday, August 13th. This is a boost from Chemed's previous quarterly dividend of $0.34.
View Chemed's dividend history.

Chemed pays an annual dividend of $1.44 per share and currently has a dividend yield of 0.31%. Chemed has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Chemed is 7.96%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Chemed will have a dividend payout ratio of 7.45% next year. This indicates that Chemed will be able to sustain or increase its dividend.
View Chemed's dividend history.

Chemed issued an update on its FY 2021 earnings guidance on Tuesday, August, 3rd. The company provided EPS guidance of $18.200-$18.500 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $17.350. The company issued revenue guidance of -.

2 brokerages have issued 12-month price targets for Chemed's shares. Their forecasts range from $580.00 to $609.00. On average, they anticipate Chemed's share price to reach $594.50 in the next twelve months. This suggests a possible upside of 25.7% from the stock's current price.
View analysts' price targets for Chemed or view top-rated stocks among Wall Street analysts.

1 employees have rated Chemed CEO Kevin J. McNamara on Glassdoor.com. Kevin J. McNamara has an approval rating of 100% among Chemed's employees. This puts Kevin J. McNamara in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Chemed include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), R1 RCM (RCM), Amedisys (AMED), AMN Healthcare Services (AMN), LHC Group (LHCG), CorVel (CRVL), MEDNAX (MD), Tivity Health (TVTY) and Cross Country Healthcare (CCRN).
View all of CHE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include AT&T (T), The Home Depot (HD), Johnson & Johnson (JNJ), AbbVie (ABBV), Abbott Laboratories (ABT), CVS Health (CVS), The Boeing (BA), UnitedHealth Group (UNH), Verizon Communications (VZ) and Chevron (CVX).

Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."

Chemed's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.57%), BlackRock Inc. (9.01%), Neuberger Berman Group LLC (3.77%), Kayne Anderson Rudnick Investment Management LLC (2.78%), State Street Corp (2.71%) and Wells Fargo & Company MN (2.53%). Company insiders that own Chemed stock include Andrea R Lindell, Donald E Saunders, Frank E Wood, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee and Thomas P Rice.
View institutional ownership trends for Chemed.

CHE stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Citadel Advisors LLC, Invesco Ltd., FMR LLC, Renaissance Technologies LLC, Virginia Retirement Systems ET AL, Teacher Retirement System of Texas, and Deutsche Bank AG. Company insiders that have sold Chemed company stock in the last year include Donald E Saunders, Kevin J Mcnamara, Nicholas Michael Westfall, Spencer S Lee, and Thomas P Rice.
View insider buying and selling activity for Chemed or view top insider-selling stocks.

CHE stock was bought by a variety of institutional investors in the last quarter, including Boston Trust Walden Corp, Ninety One UK Ltd, Kayne Anderson Rudnick Investment Management LLC, Bank of America Corp DE, Bank of America Corp DE, State Street Corp, Woodline Partners LP, and Point72 Asset Management L.P..
View insider buying and selling activity for Chemed or or view top insider-buying stocks.

Shares of CHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CHE stock can currently be purchased for approximately $473.08.

Chemed has a market capitalization of $7.44 billion and generates $2.08 billion in revenue each year. The company earns $319.47 million in net income (profit) each year or $18.08 on an earnings per share basis.

Chemed employs 15,544 workers across the globe.

Chemed was founded in 1970.

The official website for Chemed is www.chemed.com.

Chemed is headquartered at 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202.

Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The company can be reached via phone at (513) 762-6690.